Generics BulletinTeva will have to wait more than a decade to launch its proposed generic version of Amicus Therapeutics’ ultra-rare genetic disorder treatment Galafold (migalastat) 123mg capsules, after reaching a se
Pink SheetThe US first-approver advantage over the European Union remains stark, with eight of ten novel agents first cleared by the US Food and Drug Administration, according to a Pink Sheet analysis of rece
ScripThe world of mid-cap biotech is no stranger to share price volatility, but a handful of companies have enjoyed the upside, emerging as rising stars this year thanks to eye-catching early results. A re
Pink SheetState policy and patient advocacy work will become more prominent in relatively new CEO John Crowley's restructured Biotechnology Innovation Organization. Crowley, who took over as CEO in March, descr